Canada Markets close in 57 mins

BriaCell Therapeutics Corp. (BCT.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
8.36+0.33 (+4.11%)
As of 02:33PM EDT. Market open.
Full screen
Previous Close8.03
Open8.18
Bid8.30 x N/A
Ask8.47 x N/A
Day's Range8.06 - 8.42
52 Week Range5.32 - 15.75
Volume1,620
Avg. Volume4,876
Market Cap133.031M
Beta (5Y Monthly)1.35
PE Ratio (TTM)N/A
EPS (TTM)-0.38
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.07
  • Baystreet

    Stocks in play: BriaCell Therapeutics Corp

    Announces that its lead product candidate, Bria-IMT™, will be featured in three posters during the 2022 ...

  • GlobeNewswire

    BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium® December 6th and 7th

    PHILADELPHIA and VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that its lead product candidate, Bria-IMT™, will be featured in three posters during the 2022 San Antonio Breast Cancer Symposium® taking place December 6-10, 2022 at the Henry B. Gonzalez Convention Center in Sa

  • GlobeNewswire

    BriaCell Partners with Caris Life Sciences® to Expand Patient Outreach and Molecular Profiling

    PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces that it has signed an agreement with Caris Life Sciences® (Caris), a leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare. “Our goal is to develo